This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fung, P. Y. S. Articles by Longenecker, B. M. Search for Related Content PubMed PubMed Citation Articles by Fung, P. Y. S. Articles by Longenecker, B. M.

Specific Immunosuppressive Activity of Epiglycanin, a Mucin-like Glycoprotein Secreted by a Murine Mammary Adenocarcinoma (TA3-HA)¹

Department of Immunology, University of Alberta, Edmonton, Alberta, Canada T6G 2H7 [P.Y.S.F., B.M.L.], and Biomira, Inc., Research Centre One, Edmonton Research and Development Park, Edmonton, Alberta, Canada T6N 1E5 [B.M.L.]

Epiglycanin (Epi) is a mucin-like glycoprotein carrying multiple Thomsen Freidenreich (TF) and Tn determinants secreted by a murine mammary adenocarcinoma, TA3-Ha. As an attempt to further characterize immunoregulatory networks in the TA3-Ha animal model, we tested whether Epi causes active suppression of the cell-mediated immune response against TF determinants. In this study, we show that (a) s.c. injection of epiglycanin emulsified in either complete Freund's adjuvant or Ribi adjuvant containing trehalose dimycolate and monophosphoryl lipid A elicits a classical specific delayed-type hyperactivity response to TF haptens either naturally expressed on epiglycanin or as synthetic haptens conjugated to a protein carrier; (b) i.v. injection of as little as 500 ng of Epi induces specific immunosuppression to anti-Epi and anti-TF synthetic antigen delayed-type hyperactivity responses; (c) this immunosuppression can be abrogated by i.v. injection of cyclophosphamide prior to immunizations; (d) Epi-induced specific immunosuppression can be adoptively transferred by nylon wool-nonadherent cells 6 days following i.v. injection of Epi; (e) pretreatment of suppressor cell populations with anti-Thy-1, anti-L3T4, anti-Lyt-1, or anti-I-J^k but not anti-Lyt-2 monoclonal antibodies plus complement prior to adoptive transfer abolished immunosuppression; (f) i.v. injection of immunosuppressive amounts of Epi on Days 2 and 6 after transplantation of TA3-Ha cells increased the lethality of the tumor transplant. These results suggest that Epi-induced specific immunosuppression in the TA3-Ha animal model is mediated by Thy-1⁺, L3T4⁺, Lyt-1⁺2^-, and I-J^k+ suppressor cells. The results are also consistent with the suggestion that this immunosuppression may enhance TA3-Ha tumor growth.

¹ This work was supported by a grant from the National Cancer Institute of Canada and by Biomira, Inc.

² To whom requests for reprints should be addressed, at Department of Immunology, 860 Medical Sciences Building, University of Alberta, Edmonton, Alberta, Canada T6G 2H7.

Received 9/10/90. Accepted 12/ 5/90.

This article has been cited by other articles:

				Y. Itoh, M. Kamata-Sakurai, K. Denda-Nagai, S. Nagai, M. Tsuiji, K. Ishii-Schrade, K. Okada, A. Goto, M. Fukayama, and T. Irimura Identification and Expression of Human Epiglycanin/MUC21: a Novel Transmembrane Mucin Glycobiology, January 1, 2008; 18(1): 74 - 83. [Abstract] [Full Text] [PDF]

				T. A. Gilewski, G. Ragupathi, M. Dickler, S. Powell, S. Bhuta, K. Panageas, R. R. Koganty, J. Chin-Eng, C. Hudis, L. Norton, et al. Immunization of High-Risk Breast Cancer Patients with Clustered sTn-KLH Conjugate plus the Immunologic Adjuvant QS-21 Clin. Cancer Res., May 15, 2007; 13(10): 2977 - 2985. [Abstract] [Full Text] [PDF]

				R. J. Longman, R. Poulsom, A. P. Corfield, B. F. Warren, N. A. Wright, and M. G. Thomas Alterations in the Composition of the Supramucosal Defense Barrier in Relation to Disease Severity of Ulcerative Colitis J. Histochem. Cytochem., December 1, 2006; 54(12): 1335 - 1348. [Abstract] [Full Text] [PDF]

				I. Sugihara, M. Yoshida, T. Shigenobu, H. Takagi, K. Maruyama, N. Takeuchi, M. Toda, M. Inoue, and H. Nakada Different Progression of Tumor Xenografts between Mucin-Producing and Mucin-Non-Producing Mammary Adenocarcinoma-Bearing Mice. Cancer Res., June 15, 2006; 66(12): 6175 - 6182. [Abstract] [Full Text] [PDF]

				C. A. Carlos, H. F. Dong, O. M. Z. Howard, J. J. Oppenheim, F.-G. Hanisch, and O. J. Finn Human Tumor Antigen MUC1 Is Chemotactic for Immature Dendritic Cells and Elicits Maturation but Does Not Promote Th1 Type Immunity J. Immunol., August 1, 2005; 175(3): 1628 - 1635. [Abstract] [Full Text] [PDF]

				P. Brossart, K. S. Heinrich, G. Stuhler, L. Behnke, V. L. Reichardt, S. Stevanovic, A. Muhm, H.-G. Rammensee, L. Kanz, and W. Brugger Identification of HLA-A2-Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies Blood, June 15, 1999; 93(12): 4309 - 4317. [Abstract] [Full Text] [PDF]

				C.-J. Yu, J.-Y. Shew, C.-T. Shun, H.-T. Lin, S.-H. Kuo, K.-T. Luh, and P.-C. Yang Quantitative Analysis of mRNA Encoding MUC1, MUC2, and MUC5AC Genes: A Correlation between Specific Mucin Gene Expression and Sialomucin Expression in Non-Small Cell Lung Cancer Am. J. Respir. Cell Mol. Biol., May 1, 1998; 18(5): 643 - 652. [Abstract] [Full Text]

				A. P. Spicer, G. J. Rowse, T. K. Lidner, and S. J. Gendler Delayed Mammary Tumor Progression in Muc-1 Null Mice J. Biol. Chem., December 15, 1995; 270(50): 30093 - 30101. [Abstract] [Full Text] [PDF]

				K. L. Carraway, N. Fregien, K. L. Carraway, and C. A. Carraway Tumor sialomucin complexes as tumor antigens and modulators of cellular interactions and proliferation J. Cell Sci., October 1, 1992; 103(2): 299 - 307. [PDF]